Sino-US artificial intelligence (AI) firm XtalPi Inc. has entered into a memorandum of understanding (MOU) with the Experimental Drug Development Centre (EDDC) in Singapore to form a collaborative partnership. The two entities have pledged to expand their collaboration to include the application of automated synthesis experiments and large language models in the field of drug discovery. Financial details of the agreement were not disclosed.
Building on Existing Partnership for AI+Robot-Driven Drug Development
XtalPi and the EDDC initially partnered in 2022 to focus on AI+robot-driven non-small cell lung cancer (NSCLC) drug development. This new venture will see XtalPi and EDDC broaden their cooperation to include automated chemical synthesis and AI drug design. The collaboration aims to integrate XtalPi’s automated library synthesis, drug research and development synthesis services, and other solutions within the EDDC’s operations. XtalPi will also explore potential projects with EDDC that utilize advanced AI algorithms, such as large language models, for drug research and development. By combining high-throughput and automated cutting-edge experimental technologies, the partnership will explore the potential value of cell phenotype and multi-omics data. This approach aims to gain new perspectives with richer data and develop AI and data-driven new technologies and research methods in target discovery and molecular design.- Flcube.com
